Literature DB >> 3383988

Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

D J Back1, J Tjia, H Mönig, E E Ohnhaus, B K Park.   

Abstract

The effects of sulphaphenazole, cimetidine and primaquine on the disposition of antipyrine and tolbutamide in healthy volunteers have been investigated. The model substrates were administered simultaneously in order more clearly to define any selective effects of the potential inhibitors. Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1). Clearance to hydroxytolbutamide (OHTOL) and carboxytolbutamide (COOHTOL) was also significantly decreased. In contrast, sulphaphenazole had no effect on the disposition of antipyrine. Administration of cimetidine did not significantly alter the disposition of either model drug. However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively). Clearance to OHTOL and hydroxymethylantipyrine (HMA) was reduced. A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1). The partial clearance to HMA, 4-hydroxyantipyrine (OHA) and norantipyrine (NORA) was also significantly reduced. The two main inferences are first, that tolbutamide and antipyrine are metabolised by different forms of cytochrome P-450, and second that a battery of model substrates is needed to investigate the inhibitory effects of a drug in man.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383988     DOI: 10.1007/bf00614553

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  46 in total

1.  Partial purification of human liver cytochrome P 450.

Authors:  P Beaune; P Dansette; J P Flinois; S Columelli; D Mansuy; J P Leroux
Journal:  Biochem Biophys Res Commun       Date:  1979-06-13       Impact factor: 3.575

2.  The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes.

Authors:  G W Mihaly; S A Ward; D D Nicholl; G Edwards; A M Breckenridge
Journal:  Biochem Pharmacol       Date:  1985-02-01       Impact factor: 5.858

3.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

5.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 6.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.

Authors:  B Gachályi; A Vas; K Csillag; B Nagy; F Kocsis; A Káldor
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.

Authors:  B Osikowska-Evers; P Dayer; U A Meyer; G M Robertz; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1987-03       Impact factor: 6.875

9.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes.

Authors:  P H Beaune; P G Kremers; L S Kaminsky; J De Graeve; A Albert; F P Guengerich
Journal:  Drug Metab Dispos       Date:  1986 Jul-Aug       Impact factor: 3.922

View more
  18 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  A screening test for slow metabolisers of tolbutamide.

Authors:  M A Page; J S Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

5.  Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors:  Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.

Authors:  L M Tremaine; K D Wilner; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

7.  N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.

Authors:  H J Gill; M D Tingle; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

8.  Effect of chlormethiazole on hepatic monooxygenases activity in vivo.

Authors:  H Mönig; D J Back; H T Heidemann; E E Ohnhaus; B Brockmann; H M Schulte
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

Review 10.  P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.

Authors:  M Murray
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.